Post-IPO Ophthalmic Bio, Executives and VCs Simultaneously Expand Holdings

Chronic eye‐disease treatment platform company SpyGlass Pharma, Inc. (NASDAQ: SGP) saw its reporting person, Khan Bilal Arshad, boost his economic stake by acquiring over 130,000 shares of its common stock—approximately $2.16 million (about ₩2.8 billion)—through both direct and indirect accounts immediately following its NASDAQ debut.

On the same day, venture‐capital firm Vensana Capital automatically converted its existing preferred convertible shares into roughly 3.04 million common shares and purchased an additional 165,000 shares at the $16 offering price, bringing its indirect holding to about 3.31 million shares.

Coinciding with the IPO, SpyGlass Pharma amended its articles of incorporation and internal regulations, appointed Habib Dable as a new independent director and compensation committee member, and designated its SEC filings, press releases, and website as official channels for listing‐related disclosures.

On February 9, the company closed its NASDAQ offering by issuing 10,781,250 shares of common stock at $16 per share, raising $172.5 million (approximately ₩220 billion). The offering price had been set at $16 based on a target of raising about $150 million (around ₩200 billion) from 9,375,000 shares.

The stock jumped more than 50% above the $16 offering price on its first trading day, reaching the $24 level, and saw gains exceeding 70% in after‐hours trading, exhibiting high volatility immediately after listing.

Headquartered in Aliso Viejo, California, SpyGlass Pharma is a late‐stage biopharmaceutical company developing non‐biodegradable ocular drug‐delivery devices that release medication over several years for patients with chronic ophthalmic conditions such as open‐angle glaucoma and elevated intraocular pressure.

Founded in 2019, the company’s key pipeline assets include the BIM IOL system—an intraocular lens with an attached drug pad implanted during cataract surgery—and a ring-shaped, long-acting implant. The IPO proceeds will fund Phase 3 clinical trials and commercialization of this drug‐delivery platform.